Neo Ivy Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $289K | Sell |
5,254
-19,834
| -79% | -$1.09M | 0.09% | 252 |
|
|
2025
Q1 | $1.77M | Buy |
+25,088
| New | +$1.77M | 0.56% | 77 |
|
|
2024
Q4 | – | Sell |
-21,020
| Closed | -$1.48M | – | 280 |
|
|
2024
Q3 | $1.48M | Buy |
21,020
+20,116
| +2,225% | +$1.41M | 0.48% | 85 |
|
|
2024
Q2 | $74K | Buy |
+904
| New | +$74K | 0.01% | 211 |
|
|
2022
Q4 | – | Sell |
-798
| Closed | -$68K | – | 345 |
|
|
2022
Q3 | $68K | Buy |
798
+55
| +7% | +$4.69K | 0.18% | 189 |
|
|
2022
Q2 | $61K | Buy |
+743
| New | +$61K | 0.16% | 208 |
|
|
2021
Q4 | – | Sell |
-1,044
| Closed | -$129K | – | 448 |
|
|
2021
Q3 | $129K | Buy |
+1,044
| New | +$129K | 0.15% | 212 |
|
|
2021
Q2 | – | Sell |
-505
| Closed | -$38K | – | 456 |
|
|
2021
Q1 | $38K | Sell |
505
-182
| -26% | -$13.7K | 0.04% | 355 |
|
|
2020
Q4 | $60K | Buy |
+687
| New | +$60K | 0.07% | 293 |
|
|
2020
Q3 | – | Sell |
-1,044
| Closed | -$129K | – | 471 |
|
|
2020
Q2 | $129K | Buy |
1,044
+688
| +193% | +$85K | 0.15% | 212 |
|
|
2020
Q1 | $30K | Buy |
+356
| New | +$30K | 0.05% | 352 |
|
|
2019
Q3 | – | Sell |
-3,527
| Closed | -$302K | – | 292 |
|
|
2019
Q2 | $302K | Buy |
+3,527
| New | +$302K | 0.17% | 187 |
|